Needed: New and better tools to combat latent tuberculosis infection

Annals of Internal Medicine

Volumn 149, Issue 10, 2008, Pages 761-763

  Blumberg, Henry M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRROLE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; WARFARIN;

CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; EDITORIAL; EVIDENCE BASED MEDICINE; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; KIDNEY FAILURE; LATENT TUBERCULOSIS INFECTION; LIVER TOXICITY; MONOTHERAPY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS;

EID: 56549090767     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-149-10-200811180-00011     Document Type: Editorial

References (23)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51. [PMID: 10881762]
2. Canadian Thoracic Society and Public Health Agency of Canada. Canadian Tuberculosis Standards, 6th ed. 2007. Accessed at www.phac-aspc.gc.ca/ tbpc-latb /pubs/pdf/tbstand07_e.pdf on 15 October 2008.
3. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293:2776-84. [PMID: 15941808]
4. Sterling TR. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med. 2008;29:532-41. [PMID: 18810686]
5. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283:1445-50. [PMID: 10732934]
6. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735-9. [PMID: 12904741]
7. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36-41. [PMID: 1731596]
8. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. A randomized trial. Ann Intern Med. 2008;149:689-97.
9. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-50. [PMID: 10524579]
10. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med. 1996;154:1473-7. [PMID: 8912767]
11. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 1997;155:1735-8. [PMID: 9154885]
12. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006; 166:1863-70. [PMID: 17000943]
13. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62. [PMID: 12588714]
14. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640-7. [PMID: 12379063]
15. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126-36. [PMID: 18277121]
16. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1, 000 patients. JAMA. 1979;241:1239-41. [PMID: 762788]
17. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978; 117:991-1001. [PMID: 666111]
18. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337:801-8. [PMID: 9295239]
19. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715-22. [PMID: 17712755]
20. Sterling TR, Hackman J, Horsburgh CR, Chaisson RE, Wang YC, Quinn E, et al. Tuberculosis Trials Consortium. Design of Tuberculosis Trials Consortium Study 26: once-weekly rifapentine plus isoniazid (INH) for 3 months vs. daily INH for 9 months for the treatment of latent TB infection. Presented at the 4th World Congress on Tuberculosis, Washington, DC, 3-5 June 2002: Abstract 143.
21. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177:348-55. [PMID: 17989346]
22. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173:927-31. [PMID: 16424442]
23. Burman W, McNeeley D, Moulton LH, Spigelman M, Vernon A. Advancing the science in clinical trials for new TB drugs [Editorial]. Int J Tuberc Lung Dis. 2008;12:111-2. [PMID: 18230241]